

1 Characterization of a novel intratracheal aerosol challenge model of *Brucella melitensis* in
2 guinea pigs

3

4

5 Hensel, M.E.^a, Garcia-Gonzalez, D.G.^a, Chaki, S.P.^a, Samuel, J.^b, and Arenas-Gamboa, A.M.^{a#}

6 a. Texas A&M University, College of Veterinary Medicine and Biomedical Sciences,
7 Department of Veterinary Pathobiology, College Station, Texas, USA

8 b. Texas A&M University, Health Science Center and College of Medicine, Department of
9 Microbial Pathogenesis and Immunology, College Station, Texas, USA

10

11

12 Running head. Intratracheal inoculation with *B. melitensis* in guinea pigs

13

14 #Address correspondence to Angela Arenas-Gamboa, aarenas@cvm.tamu.edu

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **Abstract**

48 *B. melitensis* is considered the most virulent of the *Brucella* species, and a need exists for an
49 improved laboratory animal model of infection that mimics natural transmission and disease.
50 Guinea pigs are highly susceptible to infection with *Brucella* spp. and develop a disease
51 syndrome that mimics natural disease after aerosol inoculation. Intratracheal inoculation is a
52 targeted means of generating aerosols that offer advantages over aerosol chamber delivery. To
53 establish this delivery method, female, Hartley guinea pigs were infected via intratracheal
54 inoculation with PBS or 16M *B. melitensis* at low dose (10^1 to 10^3) or high dose (10^6 to 10^8) and
55 monitored for 30 days for signs of disease. Guinea pigs in the high dose groups developed fever
56 between 12-17 days post-inoculation. Bacteria were recovered from the spleen, liver, lymph
57 nodes, lung, and uterus at 30-days post-inoculation and demonstrated dose dependent mean
58 increases in colonization and pathologic changes consistent with human brucellosis. To study the
59 kinetics of extrapulmonary dissemination, guinea pigs were inoculated with 10^7 CFU and
60 euthanized at 2-hours post inoculation and at weekly intervals for 3 weeks. 5.8×10^5 to 4.2×10^6
61 CFU were recovered from the lung 2 hours post-inoculation indicating intratracheal inoculation
62 is an efficient means of infecting guinea pigs. Starting at 1-week post inoculation bacteria were
63 recovered from the aforementioned organs with time dependent mean increases in colonization.
64 This data demonstrates that guinea pigs develop a disease syndrome that models the human
65 manifestation of brucellosis, which makes the guinea pig a valuable model for pathogenesis
66 studies.

67 **Author summary**

68 Brucellosis is caused by a gram-negative, intracellular bacterial pathogen with a worldwide
69 distribution and affects up to half a million people per year. It is a neglected zoonosis that

70 impacts not only animal welfare, but also exert economic pressure on afflicted individuals
71 through loss of wages and decreased productivity. In people, recurrent fever, malaise, and
72 anorexia accompanied by enlargement of the spleen and lymph nodes are common clinical
73 symptoms of infection. The mouse model has been used extensively to study the pathogenesis of
74 brucellosis, but there are drawbacks to extrapolating studies in mice to develop vaccines or
75 therapeutics for people. Mice are frequently inoculated via intraperitoneal injection, which is an
76 artificial means of producing disease that does not mimic natural transmission or disease
77 features, such as fever. An animal model is needed that can be infected through natural
78 transmission routes and subsequently develop a syndrome that matches clinical disease seen in
79 people in order to study the pathogenesis of disease and to develop vaccines and therapeutics.
80 The guinea pig offers an improvement on the mouse model because it can be infected via aerosol
81 inoculation and develops fever, a humoral immune response, systemic colonization, and
82 macroscopic and microscopic lesions of disease. As such, guinea pigs could be used a more
83 biologically relevant model for evaluation of host-pathogen interactions.

84 **Introduction**

85 Brucellosis is a disease caused by a gram-negative coccobacillus of the genus *Brucella*
86 and is a zoonotic pathogen that has a worldwide distribution [1]. Of the twelve currently
87 recognized *Brucella* species, *Brucella melitensis* is considered the most virulent [2]. The natural
88 hosts of *B. melitensis* are sheep and goats [2]. The primary clinical presentation in affected small
89 ruminants are abortion, stillbirths, and decreased fertility; bacteria are shed in large numbers
90 after abortions in the placenta or through secretory products like milk [2]. People are commonly
91 exposed through aerosols or by ingestion of unpasteurized milk or milk products [2]. In humans,
92 clinical brucellosis typically manifests as relapsing periods of fever, malaise, and inappetance

93 [2]. More severe complications such as disease of the reproductive, osteoarticular,
94 cardiovascular, or nervous systems are also possible [2, 3].

95 Aerosols are a common means of transmission in people and animals and inhalation of
96 bacteria leads to colonization of the reticuloendothelial organs such as the spleen, liver, and
97 lymph nodes [2]. Certain occupations are at a greater risk of exposure due to close proximity
98 with animals including veterinarians, farmers, and abattoir workers [2]. Humans who are
99 exposed to aerosols generated following an animal abortion event are often exposed to up to 10⁹
100 colony forming units (CFU), but a dose of 10-100 CFU is reported to generate disease [2, 4].
101 Due to the ease of aerosolization and the low infectious dose, *B. melitensis* could potentially be
102 weaponized and is designated a Category B agent by the Centers for Disease Control and
103 Prevention [4].

104 Animal models utilized to study human brucellosis include mice, guinea pigs, rabbits,
105 rats, and nonhuman primates [5]. Mice are currently the most commonly used model for
106 brucellosis due to the ready availability of many genetic and immunologic tools [5]. A drawback
107 to murine research is the large number of infectious organisms required to induce disease, which
108 is well above the dose required to cause infection in people, and mice do not develop fever [6, 7].
109 Additionally, the most common means of inoculating mice with *Brucella* is intraperitoneal
110 injection, which is not a means of natural transmission and thus the results of these experiments
111 may not be as relevant. Guinea pigs were the animal model of choice to study the pathogenicity
112 of *Brucella* species from the early 1900s to 1960 but were supplanted by the mouse model [8-
113 10]. Similar to mice, guinea pigs can be infected by a variety of routes including intraperitoneal,
114 intramuscular, subcutaneous, and inhalation. In contrast to mice, guinea pigs not only develop
115 systemic disease but also demonstrate clinical signs of infection that include fever [11]. A need

116 exists for an animal model that can be infected via aerosol transmission and replicate key
117 features of human disease.

118 The experiments described herein represent a novel approach to understand the
119 pathogenesis of aerosol transmission in a guinea pig model including the dose response to
120 infection, kinetics of dissemination after aerosol exposure, and macroscopic and microscopic
121 pathologic findings. Previous studies have indicated that guinea pigs are a physiologically
122 relevant model and with an updated approach to inoculation, the guinea pig could be used to
123 investigate host-pathogen interactions.

124 **Results**

125 **Passage through the MicroSprayer® does not adversely affect bacterial viability.**

126 This study utilized the PennCentury™ MicroSprayer because it is a targeted means of
127 generating aerosols and has been used successfully to inoculate mice with bacterial pathogens
128 [12]. The MicroSprayer® device has not been previously used to inoculate guinea pigs. Our first
129 objective was to determine if passage of the inoculum through the MicroSprayer® affected the
130 bacterial viability. Bacterial suspensions of each dose were sprayed through the device and
131 collected into 900 µl of PBS, serially diluted, and plated on TSA to calculate the number of
132 viable bacteria. Bacterial viability was minimally affected by passage through the device. As an
133 example, the original inoculum for guinea pigs in the 10⁷ group contained 4.4x10⁷ CFU/50 µl
134 and after passage through the MicroSprayer® 4.1x10⁷ CFU/50 µl were recovered (Table 1). This
135 study proves that the device is a reliable means of generating an infectious aerosol and passage
136 through the MicroSprayer® does not adversely affect the viability of the bacteria.

137

138 **Table 1** Bacterial viability following passage through the MicroSprayer® Aerosolizer.

Dose group	Original	MicroSprayer®
10^1	2.0×10^2	1×10^2
10^2	2.3×10^3	2.0×10^2
10^3	7.9×10^3	1.65×10^3
10^6	4.40×10^6	3.80×10^6
10^7	4.40×10^7	4.10×10^7
10^8	4.80×10^8	4.10×10^8

139

140 **Intratracheal inoculation with 16M *Brucella melitensis* results in systemic disease.**

141 Having established that the MicroSprayer® does not adversely affect bacterial viability,
142 we next evaluated the ability of the device to inoculate guinea pigs with low doses (10^1 , 10^2 , 10^3)
143 or high doses (10^6 , 10^7 , 10^8) of *B. melitensis* 16M. After intratracheal inoculation with *B.*
144 *melitensis*, guinea pigs were monitored for signs of clinical disease including fever, loss of
145 appetite, respiratory disease (ocular discharge, increased respiratory effort), and lethargy.
146 Brucellosis is a disease of high morbidity but low mortality and, as expected, intratracheal
147 inoculation did not result in any deaths in any dose group despite evidence of systemic infection.
148 However, guinea pigs in the 10^8 group had more severe clinical signs including roughened hair
149 coat, ocular discharge, and lethargy. Body weight was not affected by infection in any dose
150 group, and all guinea pigs continued to gain weight throughout the study period (data not
151 shown). Guinea pigs inoculated with PBS or the low doses (10^1 , 10^2 , 10^3) of *B. melitensis* did not
152 develop fever or other clinical signs of brucellosis at any time point (data not shown). In the high
153 dose groups, the onset of fever (temperature $\geq 39.5^\circ\text{C}$) developed in a dose-dependent manner
154 beginning at day 16 post-infection (Fig. 1). Approximately 75% of the animals in the 10^6 and 10^7
155 groups developed fever with an undulant pattern. Based on the kinetics study, the earliest onset
156 of fever appears to be 12-days post-inoculation (data not shown). The average daily temperature
157 was significantly increased ($P < 0.05$) in the 10^6 and 10^7 groups between days 16 to 24 compared

158 to the uninfected control group. The guinea pigs in the 10^8 group did not develop fever to the
159 same level but 2 animals had a single episode of fever. We ascribe the lack of fever response in
160 the 10^8 group to overwhelming disease that resulted in sepsis.

161 A hallmark of brucellosis in natural hosts and humans is splenomegaly. Previous aerosol
162 studies with guinea pigs demonstrated the development of splenomegaly after infection [13]. In
163 response to infection, spleen weight was significantly increased ($p < 0.0001$) in the high dose
164 group (10^6 , 10^7 , 10^8) compared to the uninfected controls (Fig. 2A). The average spleen weight
165 in the 10^6 , 10^7 , and 10^8 group was 3.45 g, 2.96 g, and 3.33 g, respectively compared to 0.6 g in
166 the control group. Spleen weight continuously increased over a four-week course of infection
167 (Fig. 2B). While the liver is a frequent target of *B. melitensis*, infection is not associated with
168 hepatomegaly in humans [14]. Similarly, the liver weight was not significantly different between
169 dose groups or time points in guinea pigs (data not shown).

170 **Guinea pigs infected with *B. melitensis* develop macroscopic and microscopic lesions.**

171 *Brucella* spp. have a tropism for tissues of the reticuloendothelial system and
172 reproductive tract. To determine colonization following intratracheal inoculation, the spleen,
173 liver, lung, cervical lymph node (CLN), tracheobronchial lymph node (TBLN) and uterus were
174 collected for culture. Guinea pigs inoculated with either PBS or 10^1 and 10^2 CFU doses of *B.*
175 *melitensis* did not result in colonization of any tissue examined. Animals in the 10^3 and high dose
176 groups (10^6 , 10^7 , 10^8) demonstrated dose-dependent mean increases in CFU recovered per gram
177 of the spleen, liver, lung, cervical lymph node, tracheobronchial lymph node, and uterus at 30-
178 days post-inoculation (Fig. 3A-F). Following intratracheal inoculation, bacteria are rapidly
179 disseminated to the spleen, draining lymph nodes, and uterus within 2-hours post-inoculation and
180 could be recovered from the lung, CLN, and TBLN in 100% of the animals (Fig. 4C-F). The

181 inoculum was evenly distributed throughout all lung lobes indicating that intratracheal
182 inoculation generates a particle size that is able to reach the terminal airways (Fig. S1). Peak
183 replication occurred at 3-weeks post-inoculation in the spleen, liver, and uterus (Fig. 4A,B,D).
184 Replication continued to increase in the CLN and TBLN for the entire study period (Fig. 4E-F).

185 The earliest gross lesions developed 2-weeks post-inoculation and included nodular
186 lymphoid hyperplasia in the spleen, perinodal hemorrhage around the CLN, multifocal random
187 1-2 mm pale foci in the liver, and consolidation of the cranioventral lung lobes with multifocal 1-
188 3 mm depressed gray foci scattered throughout the pulmonary parenchyma. A single animal in
189 the 10^7 group had a splenic abscess. No gross or microscopic lesions consistent with brucellosis
190 were observed in any organ in the PBS control, 10^1 , or 10^2 groups or at 2-hours post-inoculation.
191 A grading system was developed to assess microscopic findings in the spleen, liver, lung, and
192 uterus (Table S1). Application of the grading system demonstrated a significant increase
193 ($P<0.0001$) in lesion severity based on average histologic score as the dose increased between
194 the uninfected controls and high dose groups.

195 Sections were graded by a board-certified veterinary pathologist (MH). Lesions in all
196 organs in the high dose groups (10^6 , 10^7 , 10^8) increased in number, size, and severity by 30-days
197 post-inoculation in a dose dependent manner. Histologic evaluation of the spleen revealed an
198 inflammatory infiltrate of predominantly epithelioid macrophages with fewer neutrophils that
199 effaced the normal architecture (Fig. 5). Similarly, the earliest lesion at 1-week post-inoculation
200 were small foci of epithelioid macrophages in the red pulp that increased in size and number at 2
201 and 3-weeks post-inoculation. The cortex and medulla of the lymph node were also expanded by
202 a large number of epithelioid macrophages (data not shown). The liver lesion was characterized
203 by variably sized random foci of liquefactive and coagulative necrosis surrounded by

204 neutrophilic and histiocytic inflammation and multifocal random microgranulomas composed of
205 accumulations of histiocytes (Fig. 6). Portal areas were expanded by lymphocytes and plasma
206 cells. The range of morphologic diagnoses seen in the guinea pigs is similar to those described in
207 the liver of people infected with *B. melitensis* including lymphocytic portal hepatitis and
208 microgranulomas. In addition, guinea pigs had foci of necrosis surrounded by macrophages and
209 neutrophils, which may be similar to the noncaseating granulomas described by Young [15]. The
210 earliest lesion in the lung at 1-week post-inoculation included expansion of the bronchus-
211 associated lymphoid tissue (BALT), congestion of the alveolar walls, and edema. By 2-weeks
212 post-inoculation, alveolar walls were thickened by an inflammatory infiltrate of macrophages
213 and neutrophils surrounded by lymphocytes and plasma cells. At 3 to 4-weeks, the inflammatory
214 infiltrate had coalesced into variably sized nodules of histiocytic and neutrophilic inflammation
215 (Fig. S2).

216 *Brucella* species have a known tropism for the reproductive tract. In the natural host
217 (sheep and goats), *B. melitensis* causes midterm spontaneous abortion and fetal death [10].
218 Lesions of the non-pregnant uterus have not been reported in the guinea pig model previously,
219 and most reproductive studies have focused on pregnant animals. Interestingly, at 2-weeks post-
220 inoculation, the endometrial stroma was variably expanded by edema, and endometrial glands
221 were distended by an inflammatory infiltrate of intact and degenerate neutrophils and
222 macrophages. The lesion progressed in severity and by 3 and 4-weeks post-inoculation, foci of
223 histiocytic inflammation were developing in the myometrium (Fig. 7). A single animal in the
224 10^8 -dose group had histiocytic salpingitis. No lesions were identified 1-week post-inoculation in
225 the uterus.

226 To further support the CFU data that the lesions in the liver, spleen, and uterus were due
227 to *Brucella* infection, IHC was performed to colocalize *Brucella* antigen within foci of
228 inflammation. *Brucella* antigen was detected within epithelioid macrophages in the spleen, liver,
229 and uterus by IHC further corroborating the etiology of the lesion (Fig. 5-7). Antigen was also
230 detected intracellularly within macrophages in the lung (Fig. S2), CLN, and TBLN (data not
231 shown).

232 **Infection stimulates a *Brucella*-specific IgG humoral immune response**

233 Guinea pigs develop a humoral response (anti-*Brucella* specific IgG) to infection with
234 *Brucella melitensis* delivered via intratracheal inoculation. No change in IgG level was noted in
235 the PBS, 10^1 , or 10^2 groups. Only guinea pigs in the high dose groups (10^6 , 10^7 , 10^8) were
236 capable of mounting a humoral response against *B. melitensis*. The increase in IgG level was
237 statistically significant in the 10^7 and 10^8 groups at 4-weeks post-inoculation ($P < 0.01$) (Fig 8).
238 Levels of *Brucella*-specific IgG antibodies increased starting 1-week post-inoculation and
239 increased throughout the study period (data not shown).

240 **Discussion**

241 *Brucella* organisms can be easily aerosolized and inhalation of bacteria is a major route
242 of natural transmission in both animals and people [4]. One of the limitations to developing
243 stronger intervention measures such as a safe and efficacious vaccine has been the difficulty of
244 replicating natural disease in a laboratory animal model. Mice are the most commonly utilized
245 animal, but limitations to this model include lack of fever response, relatively high dose required
246 to generate systemic infection, and an artificial route of inoculation that does not mimic natural
247 transmission events [6]. In contrast, guinea pigs develop key features of disease when inoculated
248 via an aerosol route, which closely mimics the naturally occurring disease process [13, 16, 17].

249 Guinea pigs were used in the early twentieth century as the model of choice to evaluate the
250 pathogenicity of *Brucella* species such as *B. abortus*, *B. suis*, and *B. melitensis* and could offer an
251 improvement over the mouse model for vaccine and therapeutic development [10, 11, 13, 16-24].

252 The PennCentury™ MicroSprayer is a targeted means of generating aerosols and offers
253 an improvement over aerosol chambers or aerosol devices like the Henderson apparatus because
254 it allows for the direct inoculation of bacteria into the upper respiratory tract through the trachea.
255 However, the MicroSprayer® Aerosolizer does bypass the nares, which would be a line of
256 defense in the upper respiratory tract against natural transmission. Due to the guinea pig oral
257 anatomy, the device is inserted into the proximal trachea at the level of the arytenoid cartilage.
258 Microparticles are generated after passage through the MicroSprayer®, which then move by
259 centripetal force through the trachea and into the lower airways. This is similar to the natural
260 transmission in which inhaled particles must pass from the nares into the trachea and then into
261 the bronchi and bronchioles. Particle size determines the site of deposition within the airway
262 with larger particles (>15 µm) removed through the nares and sinuses while smaller particles (6-
263 10 µm) deposit in the bronchi [25]. The smallest particle size (≤5 µm) are able to deposit in the
264 terminal bronchioles and alveoli [25]. The MicroSprayer® generates a mean particle size of 8
265 µm, which allows for the particles to be deposited in the lower airways [26].

266 Recurrent or undulant fever is a hallmark of brucellosis in humans and is a feature of
267 disease that is not replicated in the mouse model [2]. The first study to document fever in guinea
268 pigs used an intraperitoneal, intravenous, or subcutaneous route of inoculation. The severity of
269 the temperature elevation was not reported, and it was further stated that fever developed in the
270 acute stage of infection, described as 72 hours post-inoculation [11]. In people, the onset of
271 clinical symptoms such as fever tend to be insidious but likely develop between 6 to 90 days

272 after exposure, and the temporality and undulant nature of the fever response suggests guinea
273 pigs could be a biologically relevant model for future studies [4]. The aerosol literature with
274 *Brucella* spp. in guinea pigs did not evaluate body temperature and thus it was previously
275 unknown if aerosol inoculation would result in fever.

276 People can be infected with as few as 10-100 CFU of *Brucella* and thus this study
277 evaluated the ability of low doses (10^1 , 10^2 , 10^3) of *B. melitensis* 16M to infect guinea pigs [4]. A
278 high dose range (10^6 , 10^7 , 10^8) was also evaluated because many of the infectious aerosols that
279 people are exposed to likely exceed the minimum dose estimated to generate infection [2, 4]. The
280 dose titration study indicated a dose of at least 10^6 CFU was required to induce temperature
281 elevations although systemic infection developed in the majority of the guinea pigs inoculated
282 with 10^3 CFU. Previous aerosol studies in guinea pigs delivered a dose of between 4.5×10^3 /ml to
283 5.0×10^5 /ml, which generated an estimated dose range of 48-2800 CFU [13, 16, 17, 27]. The
284 majority of the early aerosol studies utilized the Henderson apparatus for generating aerosols,
285 which is a mask that fits over the head and neck of the guinea pig to create a small aerosol
286 chamber [13, 16, 17, 28]. As such, the guinea pigs were exposed not only through the respiratory
287 tract, but bacteria were also likely deposited on mucous membranes of the conjunctiva and oral
288 cavity and potentially ingested. The calculated dose did not account for these other potential
289 routes of exposure, which could have increased the dose inoculated. Furthermore, since the doses
290 from the earlier aerosol studies also based inoculation dose on calculations of ventilation rate and
291 respiratory tidal volume of the guinea pig, the dose could have been underestimated [29]. The
292 dose in this study is higher than the reported range required to induce infection in guinea pigs
293 because we wanted to establish a model that replicated the features of human brucellosis like
294 fever. The previous studies evaluated infection by colonization of organs such as the spleen and

295 liver, whereas this study used clinical parameters such as body temperature plus organ
296 colonization to demonstrate infection.

297 While the respiratory tract is a common portal of entry, pulmonary pathology and
298 respiratory disease are not atypical features of *Brucella* spp. infection [30, 31]. In the rare cases
299 in which respiratory disease is reported, the common presentations include pneumonia,
300 bronchopneumonia, pleural effusion, and dry coughing [31]. Respiratory signs rarely occur in
301 isolation, and patients often have concomitant disease such as hepatitis or spondylitis supporting
302 the role of the lung as a portal of entry rather than a primary target [30, 31]. Clinical signs in
303 mice with respiratory infection have not been reported [7]. In the 10⁸ group, two animals
304 developed transient ocular discharge, which can be associated with respiratory disease in guinea
305 pigs [32]. Guinea pigs had a pattern of cranioventral lung lobe consolidation and embolic foci,
306 which suggests a dual pattern of infection. The initial inoculation with *B. melitensis* via
307 intratracheal delivery likely leads to the development of cranioventral consolidation as the site of
308 initial deposition followed by an embolic pattern as the animals become bacteremic. A previous
309 aerosol study in guinea pigs by Elberg and Henderson reported no *Brucella*-specific macroscopic
310 or microscopic pulmonary pathology, and several other contemporary studies failed to evaluate
311 the lung for lesions [13, 16, 17].

312 *Brucella* has a tropism for organs of the reticuloendothelial system including the spleen,
313 lymph nodes, and liver [2, 3, 14, 15]. Splenomegaly, lymphadenomegaly, and hepatitis are
314 common macroscopic lesions in natural and experimental infection [3]. The microscopic splenic
315 lesion has not been well described in the medical literature but has been described as congestion,
316 lymphoid hyperplasia, and histiocytic splenitis in mice [6]. Guinea pigs develop splenic
317 congestion and lymphoid hyperplasia with occasional necrosis and abscesses thirty days after

318 receiving an aerosol dose of 2.16×10^3 CFU of *B. abortus* and *B. melitensis* [13].
319 Lymphadenomegaly is another well documented sequelae of infection with *Brucella* spp. in both
320 people and guinea pigs [13, 15-17]. An aerosol study by Elberg and Henderson noted the
321 development of caseous abscesses in the cervical and tracheobronchial lymph nodes; however,
322 *Brucella* was not cultured from the nodes so the etiology of the abscess cannot be definitively
323 assigned to brucellosis [13]. The final reticuloendothelial organ that is commonly affected during
324 infection is the liver. A prospective study of patients with hepatitis due to *B. melitensis* found
325 that disease is often subclinical but can cause mild derangements in hepatic enzymes such as
326 alanine aminotransferase (ALT)[14]. The acute lesion of brucellosis is described most frequently
327 as lymphocytic portal to lobular inflammation with fewer cases diagnosed with noncaseating
328 granulomas or microgranulomas [14]. The literature describes “granulomata” in the guinea pig
329 liver following aerosol inoculation but do not provide further histologic description [13].

330 *Brucella* spp. are best known as pathogens of the reproductive tract during pregnancy and
331 cause a range of adverse events such as abortion, stillbirths, and infertility in small ruminants and
332 people [2, 33]. Less is known about the tropism of *Brucella* organisms for the non-gravid uterus.
333 Reproductive studies in mouse models have not reported lesions in non-pregnant female
334 reproductive organs. Researchers in the early twentieth century did not identify lesions in the
335 reproductive tract of female guinea pigs and thus it was assumed that females were not an
336 appropriate animal model for use in reproductive pathogenesis investigations. Instead, the early
337 studies focused on male guinea pigs and identified orchitis, epididymitis, and peri-orchitis
338 subsequent to intraperitoneal, intratesticular, and aerosol inoculation [10, 11, 22, 24, 34].
339 However, a study from 1974 demonstrated that when pregnant guinea pigs are inoculated at mid-
340 gestation with 10^5 *B. abortus* 2308 via intramuscular injection, stillbirths, abortions, and vertical

341 transmission occur. Thus, guinea pigs may be suitable models for future investigations into the
342 pathogenesis and tropism of *Brucella* spp. for the gravid uterus.

343 This study describes pathologic changes of the non-gravid uterus, broadens the
344 knowledge of *Brucella* as a pathogen of the reproductive tract, and suggests that pregnancy is not
345 required to generate tropism. Since infertility is also described in non-pregnant women infected
346 with *Brucella* spp., it is possible that inflammation of the reproductive tract is a contributing
347 factor [33]. Intratracheal inoculation of the guinea pig offers an intriguing model for the study of
348 the host-pathogen interaction that leads to reproductive disease in addition to providing a reliable
349 means of generating systemic and clinical brucellosis that could be used to evaluate vaccine
350 candidates.

351 **Methods**

352 **Ethics statement**

353 This study includes the use of guinea pigs. This study was carried out in an approved facility in
354 strict accordance with all university and federal regulations. All guinea pig experimentation was
355 reviewed and approved by the Texas A&M University Laboratory Animal Care and Use
356 Committee (protocol: 2015-0036). The protocol was approved and is in accordance with the
357 Institutional Animal Care and Use Committee (IACUC) policies of Texas A&M University.
358 Texas A&M is accredited by the Association for the Assessment and Accreditation of
359 Laboratory Animal Care, International (AAALAC).

360 **Animal husbandry**

361 Outbred Harley female guinea pigs (n=44) weighing approximately 300-350 g were obtained
362 from Charles River Laboratories and housed in microisolator caging in a biosafety level three
363 facility. Guinea pigs were acclimated to the facility for 5 days prior to infection and were on a

364 12-hour—12-hour light-dark cycle with ad libitum access to pelleted food, Timothy hay, and
365 water. A modified Karnofsky performance status scoring system was used to evaluate the guinea
366 pigs daily to determine if early removal from the study was required.

367 **Bacteriology**

368 *Brucella melitensis* 16M wild-type strain, originally acquired from an aborted goat fetus, was
369 routinely grown on tryptic soy agar (TSA) (Difco Laboratories) at 37°C in an atmosphere
370 containing 5% (vol/vol) CO₂ for 72 hours [35]. Bacteria were harvested into phosphate-buffered
371 saline (PBS) (pH 7.4; Gibco) to obtain the final concentration needed for each experiment, as
372 estimated turbidometrically using a Klett meter. Serial dilution was performed to accurately
373 determine the number of organisms in the inoculum. To determine if passage through the
374 MicroSprayer® affected the inoculum dose, 100 µl of the inoculum was passed through the
375 MicroSprayer® and collected in the microcentrifuge tube containing 900 µl PBS for serial
376 dilution and culture on TSA.

377 **Dose titration**

378 Guinea pigs were divided in 7 groups (n=4) and were further subdivided into low dose (10¹,
379 10²,10³), high dose (10⁶, 10⁷, 10⁸), or control (PBS) groups. Guinea pigs were anesthetized with
380 ketamine/xylazine (50mg/kg;5mg/kg) and a subcutaneous IPTT-300 microchip was placed to
381 monitor temperature throughout the study (Bio Medic Data Systems). The 50 µl doses of *B.*
382 *melitensis* 16M were prepared from cultures resuspended into PBS and serially diluted to obtain
383 the dose groups. The inoculum was administered into the proximal trachea and lungs using the
384 PennCentury™ MicroSprayer I-1C device (Penn Century Inc.). Animals were monitored daily
385 for 30 days for changes in body temperature, respiratory pattern and effort, and weight.
386 Temperatures of ≥39.5°C were defined as fever. At 30-days post-inoculation, animals were

387 euthanized by intraperitoneal injection of sodium pentobarbitol (Beuthanasia) followed by
388 cardiac exsanguination. Samples of lung, liver, spleen, cervical lymph node, tracheobronchial
389 lymph node, and uterus were aseptically collected into 1 ml PBS, homogenized, serially diluted,
390 and 100 μ l of each dilution was plated in duplicate onto Farrell's medium (TSA plus *Brucella*
391 Oxoid supplement, equine serum, and 50% dextrose) and incubated at 37°C in an atmosphere
392 containing 5% (vol/vol) CO₂ [7]. Bacterial colonies were enumerated after 72 hours to quantify
393 tissue colonization. Spleen and liver were weighed at necropsy, and the aforementioned tissues
394 were collected and fixed in 10% neutral buffered formalin for evaluation by light microscopy.

395 **Kinetics of infection**

396 Guinea pigs were divided into four groups (n=4) and were infected via intratracheal inoculation
397 with 50 μ l of 1×10^7 CFU *B. melitensis*. The endpoints were 2-hours post-inoculation and at
398 weekly intervals thereafter for three weeks. To determine the actual number of infectious
399 organisms delivered by intratracheal inoculation, 4 animals were euthanized 2-hours post-
400 inoculation, and the lung was divided into four quarters (left and right, cranial and caudal),
401 collected into 1 ml PBS, homogenized, and serial dilutions plated on Farrell's medium. Spleen,
402 liver, CLN, TBLN, and uterus were collected for culture and histology at each of the time points,
403 as described in experiment 1.

404 **Histopathology**

405 Spleen, liver, lung, uterus, CLN, and TBLN were collected at necropsy and fixed in 10% neutral
406 buffered formalin for a minimum of 48 h. Tissues were routinely processed and embedded,
407 sectioned at 5 μ m, and stained with hematoxylin and eosin. Sections from spleen, liver, lung, and
408 uterus were graded in a blinded fashion by a board-certified veterinary pathologist (MH) on a

409 scale of 0-4 for inflammation type, necrosis, and severity (S1). The mean total score for each
410 tissue was compared between groups.

411 **Immunohistochemistry**

412 Unstained slides from spleen, uterus, liver, and lung were adhered to positively charged glass
413 slides for immunohistochemistry. Slides were deparaffinized and rehydrated through a series of
414 xylene and ethanol steps before antigen retrieval was performed using 1:10 EMS Solution A
415 (Electron Microscopy Services) in a 2100 Antigen Retriever (Aptum Biologics Ltd.), according
416 to manufacturer protocol. Endogenous peroxidases were blocked by 10 m incubation with
417 Bloxall Blocking Solution (Vector Laboratories) followed by 20 m blocking with normal goat
418 serum (Vector). After each step slides were washed with PBS plus 0.5% tween for 5 minutes.
419 Primary incubation was overnight at 4° C with *Brucella* polyclonal rabbit antibody (Bioss) at
420 1:600. Negative control tissues were incubated with rabbit nonimmune serum diluted in PBS. A
421 Vectastain ABC and Betazoid DAB chromagen kits (Biocare Medical) were used following
422 primary incubation according to the manufacturer's instructions. The slides were counterstained
423 with Meyer's hematoxylin III.

424 **Anti-*Brucella* specific IgG ELISA**

425 300 µl of blood was collected into serum separator tubes from the lateral saphenous vein at day
426 14 and from the heart at day 28 following euthanasia. Blood was centrifuged at 3000 rpm for 5
427 minutes, and the serum was collected for anti-*Brucella* specific immunoglobulin G (IgG) indirect
428 enzyme linked immunosorbent assay (iELISA). 96 well plates were pre-coated with 25 µg/well
429 of *Brucella abortus* 2308 heat killed lysate and held overnight at 4°C. Plates were washed three
430 times and then blocked with 3% skim milk (Sigma) for 2 hours at room temperature. Guinea pig
431 sera samples were diluted in blocking buffer (0.25% [wt/vol] bovine serum albumin) to 1:1000

432 and incubated at 37°C for 1 h. Plates were washed five times and then peroxidase labeled goat
433 anti-guinea pig IgG (KPL) was added at 1:2000, followed by incubation at 37°C for 1 hour. After
434 a final washing step, horseradish peroxidase substrate (Sigma) was added and plates were
435 protected from light and incubated for 30 m at 37°C. Absorbance was measured at 450 nm. All
436 assays were performed in triplicate, and the results are presented as the mean value for the three
437 wells.

438 **Statistical analysis**

439 Analysis was performed using the GraphPad Prism 6.0 Software. The difference between group
440 means was analyzed using a one-way analysis of variance (ANOVA) repeated-measures test, and
441 Dunnett's multiple comparisons was used to generate *P* values for selected mean comparisons.
442 Tukey's multiple comparison was used to generate *P* values to compare mean IgG values.

443 **Acknowledgements**

444 We thank Anthony Gregory and Erin J. van Schaik for technical guidance and support.

445

- 446 1. Whatmore AM, Koylass MS, Muchowski J, Edwards-Smallbone J, Gopaul KK, Perrett LL.
447 Extended Multilocus Sequence Analysis to Describe the Global Population Structure of the
448 Genus *Brucella*: Phylogeography and Relationship to Biovars. *Frontiers in Microbiology*.
449 2016;7:2049. doi: 10.3389/fmicb.2016.02049. PubMed PMID: PMC5174110.
- 450 2. Corbel MJ. *Brucellosis in Humans and Animals*. Geneva, Switzerland: World Health
451 Organization, 2006.
- 452 3. Young EJ. An overview of human brucellosis. *Clinical infectious diseases : an official*
453 *publication of the Infectious Diseases Society of America*. 1995;21(2):283-9; quiz 90. Epub
454 1995/08/01. PubMed PMID: 8562733.
- 455 4. Pappas G, Panagopoulou P, Christou L, Akritidis N. Biological weapons. *Cellular and*
456 *Molecular Life Sciences CMLS*. 2006;63(19):2229-36. doi: 10.1007/s00018-006-6311-4.
- 457 5. Silva TM, Costa EA, Paixao TA, Tsolis RM, Santos RL. Laboratory animal models for
458 brucellosis research. *Journal of biomedicine & biotechnology*. 2011;2011:518323. Epub
459 2011/03/16. doi: 10.1155/2011/518323. PubMed PMID: 21403904; PubMed Central PMCID:
460 PMC3043301.
- 461 6. Grillo MJ, Blasco JM, Gorvel JP, Moriyon I, Moreno E. What have we learned from
462 brucellosis in the mouse model? *Vet Res*. 2012;43:29. doi: 10.1186/1297-9716-43-29. PubMed
463 PMID: 22500859; PubMed Central PMCID: PMC3410789.

- 464 7. Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice
465 with *Brucella melitensis* and *Brucella abortus* and protective efficacy against aerosol challenge.
466 *Infection and immunity*. 2007;75(10):4923-32. Epub 2007/08/01. doi: 10.1128/iai.00451-07.
467 PubMed PMID: 17664263; PubMed Central PMCID: PMC2044518.
- 468 8. Fabyan M. A Contribution to the Pathogenesis of *B. Abortus*, Bang.-II. *J Med Res*.
469 1912;26(3):441-88 13. Epub 1912/07/01. PubMed PMID: 19972062; PubMed Central PMCID:
470 PMCPMC2099091.
- 471 9. García-Carrillo C. Laboratory animal models for brucellosis studies. Boca Raton, FL: CRC
472 Press; 1990.
- 473 10. Huddleson IF. Brucellosis in man and animals. New York: The Commonwealth Fund; 1943.
- 474 11. Meyer KF, Shaw EB, Fleischner EC. The Pathogenicity of *B. melitensis* and *B. abortus* for
475 Guinea-Pigs: Studies on the Genus *Brucella* Nov. Gen. IV. *The Journal of infectious diseases*.
476 1922;31(2):159-97.
- 477 12. Lafontaine ER, Zimmerman SM, Shaffer TL, Michel F, Gao X, Hogan RJ. Use of a safe,
478 reproducible, and rapid aerosol delivery method to study infection by *Burkholderia pseudomallei*
479 and *Burkholderia mallei* in mice. *PloS one*. 2013;8(10):e76804. Epub 2013/10/08. doi:
480 10.1371/journal.pone.0076804. PubMed PMID: 24098563; PubMed Central PMCID:
481 PMCPMC3788738.
- 482 13. Elberg SS, Henderson DW. Respiratory Pathogenicity of *Brucella*. *The Journal of infectious*
483 *diseases*. 1948;82(3):302-6.
- 484 14. Young EJ, Hasanjani Roushan MR, Shafae S, Genta RM, Taylor SL. Liver histology of acute
485 brucellosis caused by *Brucella melitensis*. *Hum Pathol*. 2014;45(10):2023-8. doi:
486 10.1016/j.humphath.2014.07.007. PubMed PMID: 25147098.
- 487 15. Young EJ. Human brucellosis. *Rev Infect Dis*. 1983;5(5):821-42. PubMed PMID: 6356268.
- 488 16. Harper GJ. *Brucella suis* infection of guinea-pigs by the respiratory route. *Br J Exp Pathol*.
489 1955;36(1):60-70. Epub 1955/02/01. PubMed PMID: 14351638; PubMed Central PMCID:
490 PMCPMC2082507.
- 491 17. Druett HA, Henderson DW, Peacock S. Studies on respiratory infection. III. Experiments
492 with *Brucella suis*. *J Hyg (Lond)*. 1956;54(1):49-57. PubMed PMID: 13319690; PubMed Central
493 PMCID: PMC2218001.
- 494 18. Smillie EW. An improvement in the method of isolating and recovering the bacillus of cattle
495 abortion through guinea pigs. *The Journal of Experimental Medicine*. 1918;28(5):585.
- 496 19. Smith T. The relation of *Bacillus abortus* from bovine sources to Malta fever. *The Journal of*
497 *Experimental Medicine*. 1926;43(2):207.
- 498 20. Huddleson IFH, E. T. The Pathogenicity of the Species of the Genus *Brucella* for Monkeys.
499 *The Journal of infectious diseases*. 1929;45(4):293-303.
- 500 21. Braude AI. Studies in the pathology and pathogenesis of experimental brucellosis. II. The
501 formation of the hepatic granuloma and its evolution. *The Journal of infectious diseases*.
502 1951;89(1):87-94. Epub 1951/07/01. PubMed PMID: 14861465.
- 503 22. Braude AI. Studies in the pathology and pathogenesis of experimental brucellosis. I. A
504 comparison of the pathogenicity of *Brucella abortus*, *Brucella melitensis*, and *Brucella suis* for
505 guinea pigs. *The Journal of infectious diseases*. 1951;89(1):76-86. PubMed PMID: 14861464.
- 506 23. Braude AI, Spink WW. Studies in the pathology and pathogenesis of experimental
507 brucellosis. III. Investigations pertaining to the function of the spleen. *The Journal of infectious*
508 *diseases*. 1951;89(3):272-6. PubMed PMID: 14888952.

- 509 24. Moulton JE, Meyer ME. The pathogenesis of *Brucella suis* infection in guinea pigs: lesions
510 of the spleen, liver, testis, and articulations. *The Cornell veterinarian*. 1958;48(2):165-95. Epub
511 1958/04/01. PubMed PMID: 13537582.
- 512 25. Lippmann M, Albert RE. The Effect of Particle Size on the Regional Deposition of Inhaled
513 Aerosols in the Human Respiratory Tract. *American Industrial Hygiene Association Journal*.
514 1969;30(3):257-75. doi: 10.1080/00028896909343120.
- 515 26. Bivas-Benita M, Zwier R, Junginger HE, Borchard G. Non-invasive pulmonary aerosol
516 delivery in mice by the endotracheal route. *European Journal of Pharmaceutics and*
517 *Biopharmaceutics*. 2005;61(3):214-8. doi: <https://doi.org/10.1016/j.ejpb.2005.04.009>.
- 518 27. Phillips GB, Broadwater GC, Reitman M, Alg RL. Cross infections among *Brucella* infected
519 guinea pigs. *The Journal of infectious diseases*. 1956;99(1):56-9. PubMed PMID: 13357772.
- 520 28. Henderson DW. An apparatus for the study of airborne infection. *J Hyg (Lond)*.
521 1952;50(1):53-68. PubMed PMID: 14908062; PubMed Central PMCID: PMCPMC2235137.
- 522 29. Cascio A, Caridi Gd, Lentini S, Benedetto F, Stilo F, Passari G, et al. Involvement of the
523 aorta in brucellosis: the forgotten, life-threatening complication. a systematic review. *Vector*
524 *Borne and Zoonotic Diseases*. 2012;12(10):827-40. many ref.
- 525 30. Erdem H, Inan A, Elaldi N, Tekin R, Gulsun S, Ataman-Hatipoglu C, et al. Respiratory
526 system involvement in brucellosis: the results of the Kardelen study. *Chest*. 2014;145(1):87-94.
527 Epub 2013/08/03. doi: 10.1378/chest.13-0240. PubMed PMID: 23907372.
- 528 31. Pappas G, Bosilkovski M, Akritidis N, Mastora M, Krteva L, Tsianos E. Brucellosis and the
529 respiratory system. *Clinical infectious diseases : an official publication of the Infectious Diseases*
530 *Society of America*. 2003;37(7):e95-9. Epub 2003/09/18. doi: 10.1086/378125. PubMed PMID:
531 13130417.
- 532 32. Yarto-Jaramillo E. Respiratory system anatomy, physiology, and disease: Guinea pigs and
533 chinchillas. *Vet Clin North Am Exot Anim Pract*. 2011;14(2):339-55, vi. Epub 2011/05/24. doi:
534 10.1016/j.cvex.2011.03.008. PubMed PMID: 21601817.
- 535 33. Arenas-Gamboa AM, Rossetti CA, Chaki SP, Garcia-Gonzalez DG, Adams LG, Ficht TA.
536 Human Brucellosis and Adverse Pregnancy Outcomes. *Current Tropical Medicine Reports*.
537 2016:1-9. doi: 10.1007/s40475-016-0092-0.
- 538 34. Cuba-Caparo A, Myers DM. Pathogenesis of epididymitis caused by *Brucella ovis* in
539 laboratory animals. *Am J Vet Res*. 1973;34(8):1077-85. PubMed PMID: 4755775.
- 540 35. Kahl-McDonagh MM, Elzer PH, Hagius SD, Walker JV, Perry QL, Seabury CM, et al.
541 Evaluation of novel *Brucella melitensis* unmarked deletion mutants for safety and efficacy in the
542 goat model of brucellosis. *Vaccine*. 2006;24(24):5169-77. Epub 2006/05/16. doi:
543 10.1016/j.vaccine.2006.04.005. PubMed PMID: 16697090.

544
545 **Table 1. Bacterial viability following passage through the MicroSprayer® Aerosolizer.**

546 **Figure 1. Body temperature changes in guinea pigs after intratracheal inoculation PBS,**

547 **10⁶, 10⁷, and 10⁸ *B. melitensis* 16M.**

548 Guinea pigs were inoculated using the MicroSprayer® Aerosolizer with low dose (10¹, 10²,10³),

549 high dose (10⁶, 10⁷, 10⁸), or control (PBS) groups. Body temperature was monitored daily using

550 an implantable subcutaneous IPTT-300 microchip. The solid line at 39.5° C indicates the
551 threshold for fever. Guinea pigs in the 10⁶ and 10⁷ groups developed fever with an undulant
552 pattern.

553 **Figure 2. Splenic weights in guinea pigs inoculated with *B. melitensis* 16M or PBS.**

554 Splenomegaly was induced by high doses (10⁶, 10⁷, 10⁸) of *B. melitensis* by 30-days post-
555 inoculation (A). Splenomegaly was detected as early as 2-weeks post-inoculation and increased
556 through the study period (B). Data bars represent the mean spleen weight plus the standard
557 deviation for all guinea pigs in each dose group. Mean spleen weight from each dose group (n=4)
558 or time point (n=4) was compared to mean spleen weight of the uninfected control guinea pigs
559 (n=3) and statistical significance was determined by ANOVA followed by Dunnett's multiple-
560 comparison test. Three asterisks, $P < 0.001$. Four asterisks, $P < 0.0001$.

561 **Figure 3. Intratracheal inoculation with *B. melitensis* 16M in female Hartley guinea pigs
562 results in systemic infection.**

563 Guinea pigs were divided in 7 groups (n=4) consisting of low dose (10¹, 10², 10³), high dose (10⁶,
564 10⁷, 10⁸), or control (PBS) groups. Guinea pigs were inoculated using the MicroSprayer®
565 Aerosolizer and were euthanized 30-days post-inoculation. Colonization was evaluated in the
566 spleen (A), liver (B), lung (C), uterus (D), cervical lymph node (E), and tracheobronchial lymph
567 node (F). The recovery of organisms is plotted as the total CFU/g (means ± standard deviation).
568 Mean recovery per gram of tissue was compared between dose groups and uninfected control
569 guinea pigs. Statistical significance was determined by ANOVA followed by Dunnett's multiple
570 comparisons. One asterisk, $P < 0.05$. Two asterisks, $P < 0.01$. Three asterisks, $P < 0.001$. Four
571 asterisks, $P < 0.0001$.

572 **Figure 4. Kinetics of systemic infection of *B. melitensis* 16M in guinea pigs infected via**
573 **intratracheal inoculation.**

574 Four female Hartley guinea pigs per time point group were inoculated intratracheally with 1×10^7
575 CFU/50 μ l. The initial lung colonization was evaluated 2-hours post-inoculation to determine the
576 inhaled dose. Guinea pigs (n=4) were euthanized at 1,2,3, and 4-weeks post-inoculation to
577 determine the numbers of *B. melitensis* in the spleen (A), liver (B), lung (C), uterus (D), cervical
578 lymph node (E), and tracheobronchial lymph node (F). Mean recovery per gram of tissue was
579 compared between time points and uninfected control guinea pigs. Statistical significance was
580 determined by ANOVA followed by Dunnett's multiple comparisons. One asterisk, $P < 0.05$.
581 Two asterisks, $P < 0.01$. Three asterisks, $P < 0.001$. Four asterisks, $P < 0.0001$.

582 **Figure 5. Spleen histopathology.**

583 Representative images of histopathology and immunohistochemistry of the spleen following
584 intratracheal inoculation with PBS (top), *B. melitensis* 16M at low dose (middle), or high dose
585 (bottom) at 30-days post-inoculation (A). Sections were scored for severity from 1-4 (Table S1)
586 based on accumulation of epithelioid macrophages, neutrophils, and necrosis (B). Infection with
587 *B. melitensis* induces accumulation of epithelioid macrophages (*). *Brucella* antigen was
588 detected within epithelioid macrophages by immunohistochemistry (arrows). Magnification 4x
589 (left, H&E, bar= 200 μ m), 20x (middle, H&E, bar= 50 μ m), 40x (right, Anti-*Brucella* IHC,
590 bar=20 μ m).

591 **Figure 6. Liver histopathology.**

592 Representative images of histopathology and immunohistochemistry of the liver following
593 intratracheal inoculation with PBS (top), *B. melitensis* 16M at low dose (middle), high dose
594 (bottom) at 30-days post-inoculation. Sections were scored for severity from 1-4 (Table S1)

595 based periportal inflammation, number and size of microgranulomas and necrosis. Foci of
596 necrosis were seen in the low and high dose groups (arrowheads), but the lesions were larger in
597 the high dose group. *Brucella* antigen was detected within necrotic hepatocytes and macrophages
598 in areas of necrosis by IHC (arrows). Magnification 4x (left, H&E, bar= 200 μ m), 20x (middle,
599 H&E, bar= 50 μ m), 40x (right, Anti-*Brucella* IHC, bar=20 μ m).

600 **Figure 7. Uterine histopathology.**

601 Representative images of histopathology and immunohistochemistry of the uterus following
602 intratracheal inoculation with PBS (top), *B. melitensis* 16M at low dose (middle), or high dose
603 (bottom) at 30-days post-inoculation. Sections were scored for severity from 1-4 (Table S1)
604 based on edema, endometrial neutrophilic inflammation, and myometrial inflammation. The high
605 dose group had increased numbers of neutrophils in the endometrium, foci of histiocytic
606 inflammation within the myometrium (*), and *Brucella* antigen was detected intracellularly via
607 IHC (arrows). Magnification 4x (left, H&E, bar= 200 μ m), 20x (middle, H&E, bar= 50 μ m), 40x
608 (right, Anti-*Brucella* IHC, bar=20 μ m).

609 **Figure 8. Humoral response to intratracheal inoculation with *B. melitensis*.**

610 Anti-*Brucella* specific IgG ELISA with sera from guinea pigs inoculated by intratracheal route
611 with *B. melitensis* 16M at doses of 10^3 , 10^6 , 10^7 , 10^8 , or uninfected control (A) at day 0, 14, and
612 30 post-inoculation. Guinea pigs in the 10^7 and 10^8 groups developed a statistically significant
613 humoral response to inoculation with *B. melitensis*. The results are expressed as the mean
614 absorbance per group (\pm standard error). Statistical significance was determined by ANOVA
615 followed by Dunnett's multiple-comparison of each group (n=4) to the uninfected controls (n=3).
616 Two asterisks, $P < 0.01$.

617 **Supporting Information Legends**

618 **Supplemental Table 1 Grading criteria for histopathology**

619 Spleen, liver, uterus, and lung were graded according to inflammation and lesion severity.

620 **S1 Fig Distribution of aerosol particles following intratracheal inoculation.**

621 Intratracheal inoculation results in even distribution of aerosolized particles throughout all lung
622 fields. The distribution of aerosolized *B. melitensis* 16M in the lung lobes of guinea pigs
623 inoculated with 1×10^7 CFU/50 μ l was evaluated at 2-hours and 1,2, and 3-weeks post-
624 inoculation. The lung was divided into four regions defined as left, right, cranial, and caudal, and
625 tissue colonization was determined by region. The horizontal bar is the mean per group with
626 standard error.

627 **S2 Fig Pulmonary histopathology.**

628 Representative images of histopathology and immunohistochemistry of the lung following
629 intratracheal inoculation with PBS (top), *B. melitensis* 16M at low dose (middle), high dose
630 (bottom) at 30-days post-inoculation. Sections were scored for severity from 1-4 (Table S1)
631 based neutrophilic inflammation, number and size of microgranulomas and necrosis, and
632 bronchoalveolar hyperplasia. Foci of histiocytic inflammation were seen in the low and high
633 dose groups (arrowheads), but the lesions were larger in the high dose group. *Brucella* antigen
634 was detected within alveolar macrophages in areas of inflammation by IHC (arrows).
635 Magnification 4x (left, H&E, bar= 200 μ m), 20x (middle, H&E, bar= 50 μ m), 40x (right, Anti-
636 *Brucella* IHC, bar=20 μ m).

637
638

bioRxiv preprint doi: <https://doi.org/10.1101/457184>; this version posted October 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




Figure 1





FIG 2 Splenic weights in guinea pigs inoculated with of *B. melitensis* 16M. Splenomegaly was

bioRxiv preprint doi: <https://doi.org/10.1101/457184>; this version posted October 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.


induced by high doses (10^6 , 10^7 , 10^8) of *B. melitensis* by 30-days post-inoculation (A).

Splenomegaly was detected as early as 2-weeks post-inoculation and increased through the study period (B). Data bars represent the mean spleen weight plus the standard error for all guinea pigs in each dose group. Mean spleen weight from each dose group (n=4) or time point (n=4) was compared to mean spleen weight of the uninfected control guinea pigs (n=3) and statistical significance was determined by ANOVA followed by Dunnett's multiple-comparison test. Three asterisks, $P < 0.001$. Four asterisks, $P < 0.0001$.

A. Spleen




B. Liver




bioRxiv preprint doi: <https://doi.org/10.1101/457184>; this version posted October 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.


C. Lung



D. Uterus



E. Cervical lymph node



F. Tracheobronchial lymph node






Figure 3



bioRxiv preprint doi: <https://doi.org/10.1101/457184>; this version posted October 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 4



bioRxiv preprint doi: <https://doi.org/10.1101/457184>; this version posted October 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

FIG 8 Anti-*Brucella* specific IgG ELISA with sera from guinea pigs inoculated by intratracheal route with *B. melitensis* 16M at doses of 10^3 , 10^6 , 10^7 , 10^8 , or uninfected control (A) at day 0, 14, and 30 post-inoculation. Guinea pigs in the 10^7 and 10^8 groups developed a statistically significant humoral response to inoculation with *B. melitensis*. The results are expressed as the mean absorbance (\pm standard error). Statistical significance was determined by ANOVA followed by Dunnett's multiple-comparison of each group (n=4) to the uninfected controls (n=3). Two asterisks, $P < 0.01$.





Figure 6





Figure 5





Figure 7